Next Century Growth Investors LLC Has $6.20 Million Stock Position in OptimizeRx Corp. $OPRX

Next Century Growth Investors LLC grew its stake in OptimizeRx Corp. (NASDAQ:OPRX) by 139.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 505,407 shares of the company’s stock after purchasing an additional 294,688 shares during the quarter. Next Century Growth Investors LLC owned about 2.71% of OptimizeRx worth $6,196,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in OPRX. Rhumbline Advisers increased its position in shares of OptimizeRx by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock valued at $487,000 after buying an additional 8,297 shares in the last quarter. American Century Companies Inc. increased its position in shares of OptimizeRx by 52.5% in the 2nd quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock valued at $325,000 after buying an additional 8,286 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of OptimizeRx by 141.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock valued at $1,493,000 after buying an additional 64,790 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of OptimizeRx in the 2nd quarter valued at $44,000. Finally, WINTON GROUP Ltd bought a new stake in shares of OptimizeRx in the 2nd quarter valued at $286,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings cut shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Stephens lowered their price objective on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 13th. UBS Group set a $10.00 price objective on shares of OptimizeRx in a research report on Wednesday, May 13th. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Wall Street Zen cut shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus target price of $13.43.

OptimizeRx Price Performance

OPRX stock opened at $5.23 on Monday. The stock has a 50-day moving average price of $5.84 and a two-hundred day moving average price of $8.93. The stock has a market cap of $98.11 million, a PE ratio of 14.94 and a beta of 1.13. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx Corp. has a 1 year low of $4.57 and a 1 year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. Equities analysts forecast that OptimizeRx Corp. will post 0.51 EPS for the current fiscal year.

OptimizeRx declared that its board has initiated a share buyback program on Thursday, March 5th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.